Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study investigates the possible protective role of N-Acetylcysteine against oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. The trial aims to evaluate whether N-Acetylcysteine can reduce the incidence and severity of neuropathy during chemotherapy.
Oxaliplatin, a common chemotherapeutic agent for colorectal cancer, often induces peripheral neuropathy, which can significantly affect patients' quality of life and limit treatment effectiveness. The neuropathy is partly caused by nerve inflammation and oxidative stress.
N-Acetylcysteine (NAC), an antioxidant, has been suggested to protect neurons from oxidative damage and reduce inflammation.
This interventional, randomized, parallel-assignment study will enroll colorectal cancer patients receiving oxaliplatin-based chemotherapy. Participants will be assigned to either receive N-Acetylcysteine alongside chemotherapy or chemotherapy alone. Primary outcomes include the incidence and severity of peripheral neuropathy measured at predefined intervals during treatment.
Secondary outcomes include biochemical markers of nerve inflammation and oxidative stress, including:
The study aims to provide evidence on whether N-Acetylcysteine can serve as a protective agent against chemotherapy-induced neuropathy, potentially improving treatment tolerance and patient outcomes.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NAC Group | Experimental | Patients receive modified FOLFOX-6 chemotherapy plus oral N-acetyl cysteine 1200 mg administered 1 hour before oxaliplatin throughout chemotherapy cycles. |
|
| Placebo Group | Placebo Comparator | Patients receive modified FOLFOX-6 chemotherapy plus oral placebo tablets administered 1 hour before oxaliplatin throughout chemotherapy cycles. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | Oral placebo tablets identical in appearance to N-acetyl cysteine, administered 1 hour before oxaliplatin throughout chemotherapy cycles. |
|
| Measure | Description | Time Frame |
|---|---|---|
| NCI-CTCAE, Version 5, 2017 | The CTCAE is an international classification system used to assess and describe adverse events resulting from medical treatments, especially in cancer therapy, chemotherapy, and radiation therapy. It provides standard criteria to grade the severity of each adverse event on a scale from 1 to 5: Grade 1 (Mild): Mild symptoms, no intervention needed. Grade 2 (Moderate): Symptoms require minimal intervention or slightly affect daily activities. Grade 3 (Severe): Symptoms significantly impact daily activities or require medical intervention. Grade 4 (Life-threatening): Life-threatening symptoms requiring urgent intervention. Grade 5 (Death): Death due to the adverse event. | Adverse events will be assessed using NCI-CTCAE v5.0 at baseline (Day 1, prior to Cycle 1) and after Cycle 2 (Day 15) and after Cycle 4 (Day 29). Each chemotherapy cycle lasts 14 days. |
| FACT/GOG-Ntx-12 | The FACT/GOG-Ntx-12 is a patient-reported outcome measure designed to assess chemotherapy-induced neurotoxicity, particularly from drugs such as platinum agents or taxanes. It consists of 12 items evaluating peripheral neuropathy symptoms, including numbness, tingling, pain, weakness in hands or feet, and difficulty with walking or handling objects. Each item is scored on a 0-4 scale (0 = not at all, 4 = very much), providing a total score reflecting the severity of neurotoxicity. It is primarily used to monitor the impact of chemotherapy on neurological function and related quality of life. | Neurotoxicity-related adverse events will be assessed using the FACT/GOG-Ntx-12 at baseline (Day 1, prior to Cycle 1) and after Cycle 2 (Day 15) and after Cycle 4 (Day 29). Each chemotherapy cycle lasts 14 days. |
| BPI-SF | The BPI-SF (Brief Pain Inventory - Short Form) is a patient-reported questionnaire used to assess pain severity and its impact on daily functioning. It includes questions about the intensity of pain (e.g., worst, least, average, and current pain) and how pain interferes with activities such as walking, work, mood, sleep, and relationships. Each item is rated on a 0-10 numeric scale (0 = no pain / no interference, 10 = worst imaginable pain / complete interference), allowing calculation of overall pain severity and interference scores. It is widely used in cancer patients and other chronic pain conditions to monitor pain and response to treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Serum IL-6 as a marker of inflammation | Serum IL-6 is a pro-inflammatory cytokine commonly used as a biomarker of inflammation. Elevated IL-6 levels indicate activation of inflammatory pathways, which can occur due to cancer, chemotherapy, or other physiological stressors. Measurement of serum IL-6 allows monitoring of systemic inflammatory responses in patients undergoing chemotherapy. | IL-6 will be measured at pre-oxaliplatin infusion (baseline) and after infusion completion (post-dose) on Day 1 of Cycle 1 in both study arms. NAC is administered orally 1 hour before baseline sample in the intervention arm. Each FOLFOX cycle is 14 days. |
Not provided
Inclusion Criteria:
Males and females aged ≥ 18 years old.
Patients with histologically confirmed diagnosis of Stage III colorectal cancer and high risk Stage II.
Patients who will be scheduled to receive modified FOLFOX-6.
Patients with no contraindication to chemotherapy.
Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5
Patients with adequate renal function (serum creatinine < 1.5 mg/dl or creatinine clearance (ClCr) ˃ 45 mL/min).
Patients with adequate liver function (serum bilirubin < 1.5 mg/dl).
Patients with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG) score.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nehal Mohamed Elmashad, Professor | Department of Clinical Oncology ,Tanta University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tanta University - Faculty of Medicine ,oncology department, Tanta university hospital. | Tanta | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28620280 | Background | Starobova H, Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci. 2017 May 31;10:174. doi: 10.3389/fnmol.2017.00174. eCollection 2017. | |
| 30551603 | Background | Tardiolo G, Bramanti P, Mazzon E. Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases. Molecules. 2018 Dec 13;23(12):3305. doi: 10.3390/molecules23123305. |
Not provided
Not provided
Individual participant data (IPD) will not be shared. This decision is due to patient privacy and confidentiality concerns, as well as the limited resources available for data sharing in this investigator-initiated study.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D010523 | Peripheral Nervous System Diseases |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
| ID | Term |
|---|---|
| D000111 | Acetylcysteine |
| ID | Term |
|---|---|
| D003545 | Cysteine |
| D000603 | Amino Acids, Sulfur |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
This is a Randomized, placebo-controlled, parallel-group study. Forty-six patients with stage III colorectal cancer and high-risk stage II will be randomly assigned in a 1:1 ratio to one of two arms:
Arm 1 (Placebo Group, n=23): Patients will receive 4-6 cycles of modified FOLFOX-6 chemotherapy (Oxaliplatin, Leucovorin, and 5-Fluorouracil) plus oral placebo tablets throughout the chemotherapy cycles.
Arm 2 (Drug / Experimental Group, n=23): Patients will receive the same chemotherapy regimen in addition to oral N-Acetyl Cysteine 1200 mg administered 1 hour before Oxaliplatin infusion throughout chemotherapy cycles.
Patients will be recruited from the Oncology Department, Tanta University Hospital, Egypt. Randomization will be done using a sealed envelope method. Standard antiemetic and gastric prophylaxis therapy (IV 5-HT3
Not provided
Not provided
Not provided
| N-Acetyl Cysteine | Drug | Oral N-acetyl cysteine 1200 mg administered 1 hour before oxaliplatin throughout chemotherapy cycles. |
|
| Modified FOLFOX-6 regimen | Drug | Oxaliplatin 85 mg/m² IV, leucovorin 400 mg/m² IV, followed by 5-fluorouracil bolus and continuous infusion every 2 weeks. |
|
| Pain severity and interference will be assessed using the BPI-SF at baseline (Day 1, prior to Cycle 1) and after Cycle 2 (Day 15) and after Cycle 4 (Day 29). Each chemotherapy cycle lasts 14 days. |
| Serum total anti-oxidant capacity (TAC) as a biomarker of oxidative stress | Serum total antioxidant capacity (TAC) is a biomarker of oxidative stress, reflecting the overall ability of the serum to neutralize free radicals and reactive oxygen species. TAC is used to evaluate oxidative damage and antioxidant defense mechanisms, which can be affected by chemotherapy. | TAC will be measured at pre-oxaliplatin infusion (baseline) and after infusion completion (post-dose) on Day 1 of Cycle 1 in both study arms. NAC is administered orally 1 hour before baseline sample in the intervention arm. Each FOLFOX cycle is 14 days. |
| Serum neurotensin as a biomarker for neuropathy | Description: Serum neurotensin (NT) is a peptide biomarker used to assess chemotherapy-induced neuropathy. Changes in serum neurotensin levels correlate with peripheral nerve damage and neurotoxic effects caused by chemotherapeutic agents. | NT will be measured at pre-oxaliplatin infusion (baseline) and after infusion completion (post-dose) on Day 1 of Cycle 1 in both study arms. NAC is administered orally 1 hour before baseline sample in the intervention arm. Each FOLFOX cycle is 14 days. |
| 33208072 | Background | Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M, Saad A. Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Curr Drug Targets. 2021;22(9):998-1009. doi: 10.2174/1389450121999201117115717. |
| 31208068 | Background | Tardiolo G, Bramanti P, Mazzon E. Migraine: Experimental Models and Novel Therapeutic Approaches. Int J Mol Sci. 2019 Jun 15;20(12):2932. doi: 10.3390/ijms20122932. |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D000596 |
| Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |